Leading researchers gathered in Long Beach, California, for the 16th annual meeting of the Network for Pancreatic Organ Donors with Diabetes (nPOD), which took place from February 19 through 22. nPOD is now the world’s largest tissue bank dedicated to the study of the human pancreas in type 1 diabetes (T1D), and researchers, clinicians, people with T1D, and other leaders in the diabetes space attended—more than 200—to hear results from the latest advances using nPOD samples.

Here are some of the highlights:

Since being established in 2007 with a $7 million grant from Breakthrough T1D, nPOD has collected and processed more than 50,000 tissue samples from organ donors who had or were at increased risk for T1D. nPOD is conducting more than 250 studies to unlock the mysteries of the human pancreas. For more information on nPOD, you can visit their website here.

You are helping us advance toward preventing, treating, and—one day—curing T1D. Find out more about Breakthrough T1D here.

Leading researchers from around the world will gather for the 16th annual meeting of the Network for Pancreatic Organ Donors with Diabetes (nPOD), taking place from February 19-22 in Long Beach, California. The latest advances—using nPOD samples—will be discussed, including:


Since it was established in 2007 with a $7 million grant from Breakthrough T1D, nPOD has collected and processed more than 50,000 tissue samples from organ donors who had or were at increased risk for type 1 diabetes, and has provided, without cost, these tissues to researchers around the world.


Keep up with the latest updates and exciting news from the nPOD annual meeting on Facebook (@BreakthroughT1DHQ), X (formerly Twitter) (@BreakthroughT1D), and LinkedIn.

Editor’s note: Written by guest blogger, Grace Bennett, Social Media Manager at Breakthrough T1D. The opinions expressed by the author are her own and are not necessarily those of  JDRF, its leadership, employees, or supporters.


Life with T1D means you don’t only observe your birthday, holidays, and anniversaries. You also usually in some way mark your “Diaversary” or the day your life with T1D began.

I’ve always felt a bit conflicted about my Diaversary. While I feel like I should do something to recognize a day that completely changed my life, it’s obviously not something I necessarily want to celebrate.

Who in their right mind would celebrate being diagnosed with a condition that adds significantly to one’s mental load (and that’s just the tip of the iceberg!)?

I tend to quietly acknowledge my Diaversary with my family and then move on.  That changed a few weeks ago, when I realized that life with type 1 diabetes (T1D) has taught me a lot of life lessons that I might not have learned otherwise. So, here are the 19 things I’ve learned over the 19+ years I’ve lived with T1D.

As Breakthrough T1D’s Social Media Manager, I can confidently say that the T1D community has a tremendous amount of wisdom about life with T1D to share beyond the points I’ve listed here. Don’t forget to go check out the comments on our Social Media channels for more advice from this incredible group of folks!

Leading diabetes researchers gathered for the annual conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD), which took place from October 18-21 in Rotterdam, The Netherlands, and had more than 1,600 attendees—its largest-ever audience.

More than 45 studies were presented by Breakthrough T1D researchers, funded now or in the past, working to find cures for type 1 diabetes (T1D) and improve the lives of those living with the condition today. Here are some of the highlights:


Dr. Herold has been supported by Breakthrough T1D since the late 1980s. In his research, he showed that he could prevent autoimmune diabetes with an immune-modifying antibody (which, later, became a humanized version, Tzield) and was the lead on the clinical trial that demonstrated that Tzield could delay the onset of T1D in people almost certain to develop the disease. In November 2022, Tzield was approved by the FDA to delay the onset of the disease (Stage 3) in at-risk (Stage 2) individuals ages 8+.


The next conferences we’ll be covering are the:

Stay tuned for a precap and recap of these terrific meetings!

Leading researchers from around the world will gather for the annual meeting of the International Society for Pediatric and Adolescent Diabetes (ISPAD). At this year’s meeting, which will take place from October 18-21 in Rotterdam, The Netherlands, more than 45 studies will be presented by Breakthrough T1D researchers, funded now or in the past, working to find cures for type 1 diabetes (T1D) and improve the lives of those living with the condition today. Let’s have a look:

Keep up with the latest updates and exciting news from the ISPAD annual conference on Facebook (@myJDRF), X (formerly Twitter) (@JDRF), and LinkedIn, with the hashtags #JDRFxISPAD and #ISPAD2023.

 

Leading researchers gathered in Hamburg, Germany, for the annual meeting of the European Association for the Study of Diabetes (EASD), which took place from October 2-6. Researchers, clinicians, and other leaders in the diabetes space from more than 120 countries attended—including experts from Breakthrough T1D and the Breakthrough T1D T1D Fund. The meeting featured more than 65 studies presented by Breakthrough T1D-funded researchers, funded now or in the past, working to find cures for type 1 diabetes (T1D) and improve the lives of those living with the disease today.

Research presented at this conference covered all areas of Breakthrough T1D’s research portfolio, from disease-modifying therapies to cell therapies to complications. Here are some of the highlights:

The next conference we’ll be covering is the International Society for Pediatric and Adolescent Diabetes (ISPAD) 49th Annual Conference, from October 18-21 in Rotterdam, The Netherlands. Stay tuned for a precap and recap of this terrific meeting!

Leading researchers from around the world will gather for the annual meeting of the European Association for the Study of Diabetes (EASD). At this year’s meeting, which will take place from October 2-6 in Hamburg, Germany, 65 studies will be presented by Breakthrough T1D researchers, funded now or in the past, working to find cures for type 1 diabetes (T1D) and improve the lives of those living with the disease today.

EASD Highlights


The Albert Renold Prize has been given out annually since 2007. A total of 15 recipients have received Breakthrough T1D funding prior to winning the prize, including six investigators who received Breakthrough T1D early-career scientist grants. (Dr. Dor was a Breakthrough T1D postdoctoral fellow from 2003-2005 and a Breakthrough T1D Career Development Award from 2005-2010 and has received many more awards since.)


Stay Updated

Keep up with the latest updates and exciting news from the EASD Conference on Facebook (@myJDRF), X (formerly Twitter) (@JDRF), and LinkedIn, with the hashtags #JDRFxEASD and #EASD2023.

Each year, the Association of Diabetes Care & Education Specialists (ADCES) meeting brings together clinicians, researchers, and industry leaders together to address key issues affecting people with diabetes. This year, the meeting took place in Houston, Texas, from August 4-7, 2023.

Meeting sessions focused on the latest advancements in technology, self-care behaviors, program management skills, and clinical therapeutic approaches, and this year featured presentations from Sanjoy Dutta, Ph.D., chief scientific officer at Breakthrough T1D, and Anastasia Albanese-O’Neill, Ph.D., APRN, CDCES, Breakthrough T1D’s director of community screening and clinical trials education.

Here are a few highlights:


Diabetic ketoacidosis (DKA) is a life-threatening condition due to the shortage of insulin, causing symptoms such as dehydration, nausea and vomiting, confusion, difficulty breathing, and—if not caught early—death. Approximately one-third of people in the U.S. present with DKA at the time of T1D diagnosis.


The American Diabetes Association’s 83rd Scientific Sessions is here! Scientists will present the latest type 1 diabetes (T1D) research, from beta cell replacement to regeneration, and glucose and complications trials, all with the goal of improving lives for the T1D community.

Here are Breakthrough T1D-funded researchers Drs. Sarit Polsky, Riitta Veijola, Maria Golson, and Patrice Fort to share their key takeaways from day 3, with their commentary in the video and below:


Sarit Polsky, M.D., MPH
Director, Pregnancy and Women’s Health Clinic, Barbara Davis Center for Diabetes, University of Colorado
Area: Automated Insulin Delivery Use among Pregnant Women with Type 1 Diabetes—Past, Present, and Future

Managing T1D with pregnancy is difficult, and artificial pancreas, or automated insulin delivery (AID), systems—for the most part—are not tailored to pregnancy. There are significant changes to insulin requirements over the course of pregnancy, making it difficult for pregnant women to achieve blood-sugar targets. Continuous glucose monitors (CGMs) help women increase their time spent in the optimal, pregnancy-specific time-in-range, but even with CGM some pregnant individuals do not reach their targets until the last few weeks of pregnancy.

Presenting on AID systems in pregnancy were Helen Murphy, M.D., FRACP, Carol Levy, M.D., CDCES, Sarit Polsky, M.D., MPH, and Denise Feig, M.D., M.Sc., FRCPC. They discussed the commercially available system for pregnancy (CAM APS, the only available system for pregnant women), “off-label” AID systems (like Medtronic, Tandem, Insulet, and iLet—which are not approved for pregnancy), and those in clinical trials, including one that has a special pregnancy-specific algorithm, developed by Harvard researcher (and Breakthrough T1D-funded) Eyal Dassau, Ph.D.

There are still a lot of things in the future we have to figure out—What is the optimal time-in-range? Should it be different overnight or during the day? What are the barriers to automation, such as cost and skin issues? There are currently five studies underway, with results that will be published in the next year or two.

“We’ve made a lot of progress and it’s all very exciting,” says Dr. Polsky, “so we all have a lot to look forward to.”

Riitta Veijola, M.D., Ph.D.
University of Oulu
Area: Joint ADA/Breakthrough T1D Symposium—Global Perspective on Population Level Type 1 Diabetes Screening and Monitoring

Anette-Gabriele Ziegler, M.D., Cristy Geno Rasmussen, MPH, Ph.D., and Riitta Veijola, M.D., Ph.D., presented on global screening in Europe and the United States, in a session run by Breakthrough T1D’s own Sanjoy Dutta, Ph.D., chief scientific officer at Breakthrough T1D. Dr. Veijola, who has been working on the development of T1D in children for almost 30 years, summarized the screening process. In Finland—the country with the highest rate of T1D—the most common age when islet autoantibodies appear is around 1 year, for reasons that are being explored in current studies.


2+ autoantibodies—antibodies that are directed toward your own body—means you have an almost 100 percent chance of developing T1D in your lifetime.


A screening test can tell you if you have 2+ autoantibodies. If you do, blood-sugar levels need to be monitored for the onset of type 1. You can do this in multiple ways. The traditional way is a glucometer with strips. A more modern way is continuous glucose monitoring (CGM) technology, which gives you your blood-sugar levels every 5 minutes. Another measure is to test HbA1c, which can tell you about blood-sugar levels over the past 12 weeks.

Monitoring can help you avoid diabetic ketoacidosis (DKA)—a complication of T1D when there is too much blood sugar, that can lead to death if not caught early. Monitoring also gives you time to learn about T1D and an opportunity to take part in preventive treatment, like Tzield™ (teplizumab-mzwv), or a clinical trial. To learn more about screening and monitoring, go to our T1Detect program.

Maria L. Golson, Ph.D.
Assistant Professor, Johns Hopkins School of Medicine
Area: The Islet-Cell Interactome

Alpha cells! Beta cells! Delta cells! Oh my! Maria Golson, Ph.D., and the presenters in her session, Manami Hara, DDS, Ph.D., Danielle Dean, Ph.D., and Abdelfattah El Ouaamari, Ph.D., talked about the other cells and blood vessel architecture in T1D, and how they contribute to beta cell failure.

Dr. Golson presented on delta cells, which produce somatostatin, a hormone that inhibits insulin secretion and is also released in response to high glucose as the hormone helps regulate the gastrointestinal tract. Next up was Dr. Hara, who talked about the blood vessel system in the islets, who demonstrated that there’s more interaction than previously thought between the blood vessel tissue and islet tissue. Dr. Dean spoke about glucagon, which is secreted by the alpha cell, which is also important for regulating insulin secretion. Finally, Dr. El Ouaamari found that islets have different sensory neurons, which might explain some of the differences in diabetes incidence in males and females.

Islets were previously thought to be made up of different cells, each responsible for a singular function. Now, we see that these different cells communicate with and among each other. Additional study of these interactions could help illuminate a path to new research and therapies that act upon these intercellular actions.

Patrice Fort, M.S., Ph.D.
Associate Professor and Director, Biorepository and Resource Center, University of Michigan
Area: Creating a World without Visual Loss from Diabetes

Patrice Fort, M.S., Ph.D., presented on the Mary Tyler Moore Vision Initiative (MTM Vision), with S. Robert Levine, M.D., the husband of the late Mary Tyler Moore and creator of MTM Vision, and Jennifer Sun, M.D., MPH. The first part of this initiative, due to a workshop hosted by Breakthrough T1D in 2018, is a new Diabetic Retinal Disease Staging System, to update the grading system that has not been changed for 50 years, despite the advancement of our understanding the disease and its presentation. An article outlining the new Diabetic Retinal Disease Staging System is set for publication in the coming months.

The workshop also detailed the state of the science, and outlined scientific needs and opportunities, which helped establish a “roadmap” for next steps.

One of these, presented by Dr. Fort, is collecting and characterizing different stages of the disease, to do a very in-depth analysis of those tissues to identify new potential targets to be developed with pharma companies or other academic centers. Another one, presented by Dr. Sun, is new clinical endpoints and biomarkers for better characterization of the progression of the disease. She is spearheading clinical trials that will take place at the beginning of next year.

MTM Vision’s goal is to lead to the development of therapies that will reduce or reverse vision-threatening diabetic eye disease development and progression. Ultimately, it aims to create a world without visual loss from diabetes, honoring Mary Tyler Moore’s commitment to diabetes awareness and research.

The American Diabetes Association’s 83rd Scientific Sessions is here! Until June 26, scientists will present the latest type 1 diabetes (T1D) research, from beta cell replacement to regeneration, and glucose and complications trials, all with the goal of improving lives for the T1D community.

Here are Breakthrough T1D-funded researchers Drs. Martin Thelin and Robert Eckel to share their key takeaways from day 2, with their commentary in the video and below:


Martin Thelin,
M.D., Ph.D.
Clinical Fellow–Pediatrics, University of California, San Francisco
Area: Type 1 Diabetes Through Another Lens—Lessons from Other Disease Settings

It has been known for some time that T1D is associated with increased risk of developing other autoimmune diseases, such as celiac disease, multiple sclerosis, and lupus. But cancer? It turns out that some patients on cancer immunotherapy go on to develop T1D. And there is a monogenic—meaning something that involves or is controlled by one gene—form of diabetes. It’s different from T1D or T2D, and while rare and requires a genetic test for accurate diagnosis, it can be studied for its relationship to T1D.

First up was Breakthrough T1D-funded Halis Akturk, M.D., who presented on checkpoint inhibitors—drugs that take the brakes off the immune system—in cancer and how they may lead to T1D. Next up was Martin Thelin, M.D., Ph.D., who has a Breakthrough T1D advanced postdoctoral fellowship in the laboratory of Dr. Mark Anderson, presenting on monogenic diabetes and how it can teach us about T1D. Lastly, there was Edwin Liu, M.D., who presented on celiac disease and how it correlates with T1D.

This session shone a light on how other diseases can be a resource for better understanding and managing T1D.

Robert H. Eckel, M.D.
Professor Emeritus, University of Colorado Anschutz Medical Campus
Area: Implementation of Guideline-Directed Medical Therapy for Cardiometabolic Disease—Emerging Multidisciplinary Initiatives

While he was at the University of Washington in Seattle from 1977 to 1979, Robert Eckel, M.D., was one of the first Breakthrough T1D-funded postdoctoral fellows. Now at the University of Colorado, he has been president of both the American Diabetes Association and the American Heart Association and has gone on to be an expert in cardiometabolic disorders. Cardiometabolic disorders are a cluster of interrelated factors, including high blood pressure, elevated blood-sugar levels, and high cholesterol, that put someone at high risk for having a heart attack or a stroke. Dr. Eckel also has type 1 diabetes and has had it for more than 70 years.

In Dr. Eckel’s video, he talks about a clinical trial for type 2 diabetes, in which participants had bariatric surgery (surgery intended to help a person lose weight) and were followed for 12 years to see how many people went into remission. In the beginning, the participants lost weight and there was also some remission of type 2 diabetes, which is defined by an HbA1c of under 6.5% and being off diabetes-related medicines. At one year, 50% of participants had a remission of type 2 diabetes. At 12 years, however, most of them—80%—had type 2 diabetes again.

“What are the predictors of poor outcomes?” Dr. Eckel posed. “I turned to the historical literature here. It’s people who have longer durations of diabetes and also people who are on more medications to treat their diabetes.”

This has relevance for type 1 diabetes, as longer durations of diabetes often lead to an HbA1c that is 7% or higher and may lead to complications that require diabetes-related medicines, similar to type 2. Research on these metabolic measures will ultimately benefit all of those in the diabetes space, whether it’s type 2 or type 1.